RNA Analytical/Quality Videos

  1. Goldilocks & The Guidances: Finding "Just Right" For RNA Regulations 6/24/2025

    Do we need more specific regulatory guidance for every RNA modality and therapeutic approach? We asked and the Advancing RNA Live audience answered… Here, panelists Tiffany Lucas and Ulrike Jägle address the audience’s responses, as well as share their thoughts on just how prescriptive the future of regulatory guidance for RNA therapeutics approaches could/should be..

  2. Are We Measuring What Matters? Rethinking pDNA Quality Attributes For mRNA 10/29/2026

    An audience poll reveals a three-way tie over the most critical plasmid DNA (pDNA) critical quality attributes (CQAs) for mRNA manufacturing. In this clip, Advancing RNA panelists explore whether current industry CQAs truly reflect downstream mRNA quality, highlighting ongoing debate over which metrics best predict performance and what unknowns remain for pDNA characterization.

  3. Quality Concepts In GMP IVT mRNA Development, Manufacturing, And Analytics 2/13/2025

    Stay ahead in mRNA therapeutic development by mastering the essential quality systems, process controls, and analytical methods required for robust GMP production and efficient manufacturing.

  4. The Biggest Challenges In Adopting Enzymatic Ligation of gRNA 4/29/2026

    In this Advancing RNA Live clip, panelists Venkat Krishnamurthy and April Sena home in on the economic, molecular, and biological challenges complicating the transition to enzymatic ligation today. 

  5. Enabling Real-Time Data Through A PAT Integration 11/12/2025

    Explore how Raman models and autosampling tools enable real-time bioprocess control, delivering richer data and automation. Learn how PAT technologies can help close data gaps and support smarter, more efficient biomanufacturing strategies.

  6. Therapeutic Market Opportunities For mRNA 10/16/2023

    In this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development, hundreds of audience members tell us what forms of vaccine and therapeutics they’re developing.

  7. How Is mRNA "Shaking Up" Our Regulatory Interactions & Operations Today? 5/10/2024

    The Advancing RNA Live panelists share several inconsistencies they’ve encountered working with global regulators, as well as on which aspects they’re seeing regulatory agencies applying greater scrutiny in mRNA development today.

  8. How Should We Better Interrogate gRNA Design Today? 4/29/2026

    Advancing RNA Live speaker April Sena emphasizes the need for a collaborative, public safety dataset for chemical modifications to streamline regulatory approvals, while Max De Long points out a potential drug clearance conundrum as we continue to improve our gRNA’s durability and stability. 

  9. Plasmid DNA Quality Standards: Addressing Top Questions From USP <1040> 10/29/2026

    When the United States Pharmacopeia (USP) released Chapter <1040> on plasmid DNA quality, it drew over 400 comments — eight times more than a recent AAV chapter. In this Advancing RNA Live clip, USP’s Ben Clarke shares which three core themes emerged from industry’s comments. 

  10. Where Does The mRNA Vaccine Regulatory Paradigm Fall Short For Therapeutics? 5/10/2024

    This Advancing RNA panel of experts sees a couple of important questions those striving to make RNA therapeutics will find themselves confronting when collaborating with regulators.